Watson Pharmaceuticals

Watson Pharmaceuticals, Incorporated (NYSE: WPI) is the 5th largest pharmaceutical company in the United States based on number of prescriptions dispensed. Based in Corona, California, Watson's Generics division markets over 150 pharmaceutical product families, including one of the largest lines of oral contraceptives in the industry, as well as the generic version of the popular and highly dispensed opiate narcotic pain medication, Vicodin, Hydrocodone Bitartrate/APAP tablets. Watson's Brand division markets over 20 pharmaceutical product families, including Ferrlecit for the treatment of iron deficiency anemia, Rapaflo, for the treatment of benign prostatic hyperplasia, Gelnique, the only gel for the treatment of overactive bladder, Oxytrol, a transdermal matrix patch for the control of overactive bladder, Norco, a popular opioid/narcotic pain medication, Androderm, a transdermal reservoir patch for the treatment of low testosterone, as well as many other brand name medications. In addition, Watson's Distribution division, Anda, markets more than 6,000 pharmaceutical products, making it the 4th largest pharmaceutical distribution company in the United States.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's June 30, 2012 filing.
Download all contributions to Watson Pharmaceuticals

  • Summary

    overview of the committee's finances
    Total Raised:
    $86,623
    Total Spent:
    $78,062
    Cash on Hand:
    $46,974
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Watson Pharmaceuticals Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$1,700,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Watson Pharmaceuticals

View all lobbying data for Watson Pharmaceuticals Sources: OpenSecrets.org

Regulations

3 Mentions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Watson Pharmaceuticals" in public comments on proposed federal regulations.

  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 1 HRSA Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program 2011
    • Toggle 1 FDA To Declare that Hydrocodone Bitartrate and Acetaminophen Effervescent Tablets, 2.5 mg/325 mg, 5 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg are Suitable for Submission as an Abbreviated New Drug Application 2011
    • Toggle 1 FTC Analysis of Agreement Containing Consent Orders to Aid Public Comments: Perrigo Co. and Paddock Laboratories, Inc. 2011